On January 13, 2023 QT Imaging, Inc., a medical imaging company focused on the development and clinical adoption of novel products for breast cancer imaging ("QT Imaging"), reported participation of John Klock, MD, Chief Executive Officer, in the Third Annual B. Riley Securities Oncology Conference, on January 18th and 19th (Press release, QT Imaging, JAN 13, 2023, View Source [SID1234626228]). The event will feature one-on-one discussions, fireside chats, and presentations regarding cancer treatment, testing, and monitoring modalities with public and private healthcare companies.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The live and archived webcast of the presentation will be accessible from the company’s website at View Source The replay of the webcast will be available for 30 days.

On January 13, 2023 Immix Biopharma, Inc. (Nasdaq: IMMX) ("ImmixBio", "Company", "We" or "Us"), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx)TM targeting oncology and immuno-dysregulated diseases, reported dosing of an additional patient in its ongoing Phase 1b/2a IMX-110 monotherapy clinical trial (Press release, Immix Biopharma, JAN 13, 2023, View Source [SID1234626221]). Positive safety data enabled continued dosing of previously enrolled patients. In January 2023, the seventeenth patient was dosed with IMX-110 to-date. IMX-110 clinical trial data is expected to be released on a rolling basis beginning in Q1 2023; once dosing begins, patients undergo CT scans every 8 weeks to assess tumor response to IMX-110. "We are delighted with continued robust IMX-110 clinical trial enrollment," said Ilya Rachman, MD PhD, CEO of ImmixBio. "We continue to accumulate valuable clinical data for first-in-class IMX-110 therapy. In Q1 2023 we plan to share clinical data from our IMX-110 monotherapy and IMX-110 combination trial with Beigene/Novartis’ anti-PD-1 Tislelizumab."

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

About IMX-110

The U.S. Food and Drug Administration ("FDA") approved orphan drug designation ("ODD") for IMX-110 in soft tissue sarcoma. The FDA also approved Rare Pediatric Disease Designation ("RPDD") for IMX-110 for the treatment of rhabdomyosarcoma, a life-threatening form of cancer in children. RPDD qualifies Immix Biopharma to receive fast track review, and a priority review voucher ("PRV") at the time of marketing approval of IMX-110. PRV holders can benefit from an expedited six-month review of a new drug application for any disease by the FDA. IMX-110 is currently being evaluated in a phase 1b/2a clinical trial in patients with advanced solid tumors. Learn more at www.immixbio.com/iMX-110

On January 13, 2023 Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, reported the grant of 66,800 restricted stock units of Atara’s common stock to six newly hired employees and stock options to purchase an aggregate of 40,000 shares of Atara’s common stock to one such newly hired employee (Press release, Atara Biotherapeutics, JAN 13, 2023, View Source [SID1234626217]). These awards were approved by the Compensation Committee of Atara’s Board of Directors and granted under the Atara Biotherapeutics, Inc. 2018 Inducement Plan, with a grant date of January 3, 2022, as an inducement material to the new employee entering into employment with Atara, in accordance with Nasdaq Listing Rule 5635(c)(4).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The restricted stock units vest over four years, with 25 percent vesting on the first quarterly vesting date after the first anniversary of the vesting commencement date and the remainder vesting in 12 approximately equal quarterly installments over the following three years, subject to the employee being continuously employed by Atara as of such vesting dates. The stock options vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date for such employee and the remainder vesting in 36 equal monthly installments over the following three years, subject to the employee being continuously employed by Atara as of such vesting dates. The stock options have a ten-year term and an exercise price of $3.28, equal to the per share closing price of Atara’s common stock as reported on January 3, 2022.

Atara is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).

On January 13, 2023 AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, reported that its Board of Directors has authorized a Stock Repurchase Plan under which the Company may repurchase up to $50,000,000 of the Company’s outstanding common stock, par value $0.001 per share (Press release, AnaptysBio, JAN 13, 2023, View Source [SID1234626216]). With cash, cash equivalents and investments greater than $575 million as of December 31, 2022, notwithstanding the potential full execution of the Stock Repurchase Plan, the company reiterates its previous guidance that it anticipates having approximately 4 years of capital to execute against its non-risk adjusted research and development plan, excluding potential future royalties from its GSK immuno-oncology financial collaboration.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The shares may be repurchased from time to time in open market transactions, or other means in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and Rule 10b-18 of the Exchange Act. The timing, number of shares repurchased, and prices paid for the stock under this program will depend on general business and market conditions as well as corporate and regulatory limitations, prevailing stock prices, and other considerations. The Stock Repurchase Plan will expire on December 31, 2023, may be suspended or discontinued at any time, and does not obligate the company to acquire any amount of common stock.

On january 13, 2023 IntegraGen (FR0010908723 – ALINT), an OncoDNA Group company specializing in the decryption of the human genome which performs interpretable genomic analyzes for academic and private laboratories and develops diagnostic tools for oncology, reported its unaudited revenue figures for the year 2022 (Press release, Integragen, JAN 13, 2023, View Source [SID1234626205]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The 2022 unaudited revenue amount to €12,592k in 2022, representing an increase of 16% compared to 2021. This growth in all activities reflects the firmness of the company’s positioning, both in terms of its main sequencing activities for R&D customers and its expertise in operating platforms on behalf of third parties. This amount does not include the recharge of personnel costs to the parent company.

R&D sequencing activities continued to grow due to the strong order backlog built up since 2021, with orders’ growth resumed in H2 2022. In parallel, sequencing activities performed for external platforms operated by IntegraGen increased in volume for new clinical research projects in oncology also fueling revenue growth.

As of December 31st 2022, the company’s cash position was €4,514k compared to €4,781k end of 2021, a slight decrease due to bank loans reimbursement. The position includes a state guaranteed loan (Prêt Garanti par l’État, PGE) for an outstanding amount of €1,561k that the Company started to reimburse for €339k during 2022.

With a revitalized booking orders as of the end of December, the company confirms its growth perspectives based on the current sales dynamics and existing long-term contracts along with the synergies now in place within the OncoDNA Group.

Bernard Courtieu, IntegraGen CEO, said "2022 has been another year of very strong growth at IntegraGen, and it both confirms the trust of our customers and strength of our business model, combining sequencing services for the R&D community and long-term partnerships with leading health institutions. We will continue to deliver superior value to our customers and are targeting new areas of growth, in conjunction with the OncoDNA Group".